“Pseudomonas Infections Global Clinical
Trials Review, H1, 2018”, a clinical trial report by GlobalData
provides information on the clinical trials scenario for pseudomonas
infections. The report contains data regarding the trial numbers, trial enrolments
in top countries (G7 and E7), trials by regions, by phase, trials status and
lists drugs for in-progress trials. A trend analysis of the past years’
clinical trials of the disease and future projections, through this report, can
help organizations to study the markets, find opportunities and investments.
Pseudomonas infections are bacterial
infections caused by the ‘pseudomonas’ bacterium. These are generally found in
soil, water, plants and damp areas. The infection has mild effects on a normal
human body, usually cured by a dose of antibiotics. However, it can prove to be
severe- in many cases fatal- for a body with weak immune system or already
diseased. Also, known as opportunistic bacteria, pseudomonas is generally acquired
by patients in a hospital setting.
The healthcare industry has been
facing a challenge to cure pseudomonas infections. Clinical trials are being
performed worldwide to find more effective therapeutics for the same, as the
earlier ones are proving to be ineffective. Multi Drug Resistance or MDR as it
is known, is the resistance that the bacteria causing the disease develop
towards the antibiotics, thus leading to ineffectiveness of the drug. Hence
there is a high demand for research of new antibiotics. Some of the other
challenges faced are the resurfacing of the infection that have been observed
in many cases or development of resistance mid-treatment regimen.
The companies involved in the
covered clinical trials are: Gilead Sciences Inc., Novartis AG, Cystic Fibrosis
Foundation, Insmed Inc., Polyphor AG, PARI Medical Holding GmbH, Humanigen Inc.,
F. Hoffmann-La Roche Ltd, Bayer AG and AmpliPhi Biosciences Corp.
Research for development of new
antibiotics and pseudomonas therapeutics are on a surge globally, with USA
being a dominant market in North America. Germany, France and UK are the top
European countries investing in the research and trials. Experts believe that
Asia is expected to become the focus of all the bio-medical and pharma
companies, with China, India and Japan being the top countries.
The global clinical trials market is
on rise. And as the demand for more effective cures increase globally, the
growth is expected to continue for the next decade. Increasing globalization,
technology advancements, increase in population and subsequent increase in the
diversity of medical profiles, developments in emerging economies- all are the
factors contributing to this growth. Apart from this, a positive support from
the government in terms of regulations and policies has been favourable for
businesses. Added to this are the increase in funding and investments from
private entities. A market shift might be the future, as companies are focusing
on the emerging countries for their potential markets and expansions. Also, the
new- generation technologies are now helping the small and mid- size firms and
research institutes to have access to data and research platforms, that were
earlier available to only the big players.
To know more, click on the link below:-
Related Reports:-
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing
& Communications
+91-9015378249
